Advertisement
U.S. markets closed

IRLAB Therapeutics AB (publ) (IRLAB-A.ST)

Stockholm - Stockholm Real Time Price. Currency in SEK
13.65-0.30 (-2.15%)
At close: 05:24PM CET
Advertisement
Show:
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
50,616
5,678
61,136
207,782
0
Cost of Revenue
-
-
0
39,091
0
Gross Profit
-
-
61,136
168,691
0
Operating Expense
158,375
186,444
174,359
116,239
91,562
Operating Income
-107,759
-180,766
-113,223
52,452
-91,562
Net Non Operating Interest Income Expense
-4,960
2,927
-297
-369
-194
Pretax Income
-112,719
-177,839
-113,406
51,781
-91,653
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-112,719
-177,839
-113,406
51,781
-91,653
Diluted NI Available to Com Stockholders
-112,719
-177,839
-113,406
51,781
-91,653
Basic EPS
-2.19
-3.43
-2.19
1.00
-1.92
Diluted EPS
-2.19
-3.43
-2.19
1.00
-1.92
Basic Average Shares
51,832
51,868
51,832
51,748
47,678
Diluted Average Shares
51,832
51,868
51,832
51,748
47,678
Total Operating Income as Reported
-107,758
-180,765
-113,110
52,576
-91,458
Total Expenses
158,375
186,444
174,359
155,330
91,562
Net Income from Continuing & Discontinued Operation
-112,719
-177,839
-113,406
51,781
-91,653
Normalized Income
-112,719
-177,839
-113,406
51,781
-91,653
Interest Income
2,635
3,125
0
1
1
Interest Expense
7,595
198
297
370
195
Net Interest Income
-4,960
2,927
-297
-369
-194
EBIT
-105,124
-177,641
-113,109
52,151
-91,458
EBITDA
-100,594
-173,325
-108,330
55,625
-89,202
Reconciled Cost of Revenue
-
-
0
39,091
0
Reconciled Depreciation
4,530
4,316
3,982
3,474
2,256
Net Income from Continuing Operation Net Minority Interest
-112,719
-177,839
-113,406
51,781
-91,653
Total Unusual Items Excluding Goodwill
-
-
-
0
0
Total Unusual Items
-
-
-
0
0
Normalized EBITDA
-100,594
-173,325
-108,330
55,625
-89,202
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0